<DOC>
	<DOCNO>NCT01166685</DOCNO>
	<brief_summary>Background : Retrospective analysis long-term BASKET finding identify patient large drug-eluting stent ( DES ) ( &gt; 2.5mm Stents ) patient risk late cardiac death/nonfatal myocardial infarction . In view new DES absorbable polymer new bare metal stent BMS ) thin strut biocompatible polymer , BP-II launch test comparative clinical safety 12 year treat aspirin/prasugrel combination , since prasugrel halve stent thrombosis rate compare clopidogrel large ACS trial . The primary objective demonstrate non-inferiority Nobori DES stent compare Xience Prime DES stent safety e cacy patient require stent &gt; =3.0mm diameter background contemporary dual antiplatelet therapy ( DAPT ) prasugrel aspirin Set-up : Multicenter open-label randomized trial . Patient inclusion : Unselected series patient need large ( &gt; 3mm ) stent native vessel irrespective clinical indication . Patient exclusion : In-stent restenosis , Left-main disease , cardiogenic shock , plan surgery &lt; 12months , increase bleeding risk , compliance expect , History stroke transient ischemic attack ( TIA ) . Randomization : By centre use seal envelope 1:1:1 : Nobori : Xience Prime : Prokinetik-stent .</brief_summary>
	<brief_title>Safety Efficacy Study Comparing 3 New Types Coronary Stents</brief_title>
	<detailed_description>Background Study Design The study multicentre , prospective , randomize , open-label trial compare safety efficacy Nobori® drug-eluting stent ( DES ) , Xience Prime® DES , ProKinetic® bare-metal stent ( BMS ) patient low risk restenosis , i.e . receive stent &gt; =3.0mm diameter , background contemporary antiplatelet therapy . 2289 patient recruit 8 centre 5 country randomize 2:1 DES BMS , 1:1 either DES subgroup . Randomization stratify accord centre . Analysis Datasets The full analysis set ( FAS ) include randomized patient write informed consent obtain . Patients need urgent PCI ask oral consent prior percutaneous coronary intervention ( PCI ) write informed consent afterwards . This mean randomized patient give oral write informed consent . Patients give oral informed consent die write informed consent could obtain include FAS . All patient without sign informed consent exclude regardless oral informed consent . In accordance intention-to-treat principle patient analyse accord allocated treatment group . The per-protocol set ( PPS ) include patient FAS one follow major protocol violation : - inclusion criterion meet - exclusion criterion meet - procedure perform approve Institutional Review Board ( IRB ) /Ethics Committee ( EC ) - study stent ( Nobori , Xience Prime ProKinetic ) receive - stent &lt; 3mm nominal size , provide maximum vessel size measure procedure &lt; 2.75mm - undergoing multiple step procedure different stent receive randomised second subsequent step . Inclusion patient older 75 year approve local ethic committee Canton St.Gallen , Switzerland , consequently , age &gt; 75 year add exclusion criterion center Cantonal Hospital St. Gallen . Patients receive randomly allocate stent , another study stent accord study protocol , include analyse accord stent receive ( per protocol analysis ) . Demographic Baseline Characteristics Demographic baseline data present treatment arm use FAS . Continuous variable present mean , standard deviation , median , 1st 3rd quartile . Categorical variable present frequency percentage . Comparisons continuous data do use non-parametric Kruskal-Wallis rank sum test . Comparisons categorical data do use chi-squared test expect number observation cell exceed 5 - otherwise Fisher 's exact test apply . Primary Objective The primary objective demonstrate non-inferiority Nobori DES stent compare Xience Prime DES stent safety efficacy patient require stent &gt; =3.0mm diameter background contemporary dual antiplatelet therapy ( DAPT ) prasugrel aspirin . Primary Endpoint The primary endpoint time first major adverse cardiac event ( MACE ) observe within 24 month . MACE composite endpoint include cardiac death , myocardial infarction ( MI ) target-vessel revascularization ( TVR ) . Statistical Hypothesis , Model Method Analysis Statistical Hypothesis The statistical null-hypothesis Nobori DES inferior Xience Prime DES regard MACE rate ( pi ) 24 month use prespecified non-inferiority margin ( delta ) , term absolute risk difference : H0 : pi_Nobori - pi_XiencePrime &gt; = delta The alternate hypothesis e ect Nobori DES non-inferior Xience Prime DES use non-inferiority margin . alternate hypothesis ( HA ) : pi_Nobori - pi_XiencePrime &lt; delta We use non-inferiority margin 3.8 % absolute risk difference . The sample size calculation base delta = 3.8 % , assume MACE rate Xience Prime arm 7.6 % , observe BASKET-PROVE ( BP ) trial , DES ( Kaiser et al. , 2010 ) . The stated non-inferiority margin considers 50 % relative excess event Nobori DES arm inferior . This threshold similar LEADERS trial ( Windecker et al. , 2008 ) . Statistical Model Method Analysis The absolute risk difference MACE 24 month Nobori DES Xience Prime DES compare non-inferiority margin , use two-sided 95 % confidence interval ( CI ) apply continuity-corrected modification Wilson 's score method ( Newcombe , 1998 ) . Non-inferiority declared upper limit 95 % CI absolute risk difference exceed delta . The probability MACE within 24 month calculate graphically visualize use Kaplan-Meier estimator . We estimate hazard ratio Nobori DES versus Xience Prime DES use Cox proportional hazard ( PH ) survival analysis , allow test superiority non-inferiority establish . The model contain factor `` stent type '' ( Nobori DES vs. Xience Prime DES ) stratify accord variable `` centre '' . Hazard ratio present correspond 95 % CI . The proportional hazard assumption assess two step : 1 ) Visually log-log curve 2 ) Testing Schoenfeld 's residual time-dependency . In case non-proportional hazard time-independent logistic regression model use analyze incidence primary endpoint within 24 month binary variable . An additional landmark analysis perform time-intervals 0-12 month 12-24 month . We time-strati ed Cox PH model , include interaction term factor `` stent type '' time-interval ( 0-12 vs. 12-24 month ) . The interaction term compare null hypothesis no-interaction use log-likelihood ratio test . The analysis perform PPS ( see sensitivity analysis ) . All test two-sided significance level , alpha , 0.05 . Handling Data Missing Values Data analyse potential extreme outlier . If present , outlier investigate . However , outlier include analysis , except clinical cause exclude . There miss value primary endpoint since loss follow-up incorporate Cox proportional hazard model censor time observe last follow-up/last contact date ( right censoring ) . Sensitivity Analyses S1 : All analysis repeat FAS . It important note non-inferiority analysis , estimate intention-to-treat analysis less conservative , i.e. , likely establish non-inferiority per-protocol analysis , since difference may blur include patient major protocol violation . S2 : In Cox PH model describe primary endpoint , test interaction `` stent type '' `` centre '' use log-likelihood ratio test . A significant interaction mean difference treatment-effect across centre . This determine whether treatment-effect homogeneous , important interpretation result . S3 : In case non-proportional hazard , time-independent analysis use logistic regression perform prespecified time-periods 0-12 month 0-24 month . Subgroup Analyses We investigate effect Nobori DES versus Xience Prime DES across follow prespecified subgroup : 1 . Diabetes ( yes vs. ) . 2 . Acute coronary syndrome ( ACS , ACS vs. stable coronary artery disease ) . 3 . Stent length per segment . 4 . At least one stent &lt; 3.0mm receive ( yes vs. ) . 5 . More one stented segment ( yes vs. ) . 6 . Prior myocardial infarction ( yes vs. ) . 7 . Smoking current ( yes vs. ) . 8 . Gender ( female vs. male ) Interaction term factor `` stent type '' factor include Cox regression model , together main effect `` stent type '' respective factor , compare null hypothesis no-interaction use log-likelihood ratio test . A significant interaction mean effect treatment differs subgroups . Secondary Objectives A1 : To demonstrate superiority Nobori DES ProKinetic BMS term MACE within 24 month . This comparison also act internal control non-inferiority analysis ( primary objective ) , ProKinetic BMS putative placebo . A2 : To compare Nobori DES ProKinetic BMS , Nobori DES Xience Prime DES term late harm ( cardiac death , MI stent thrombosis month 12-24 ) . B : To compare Nobori DES Xience Prime DES , Nobori DES ProKinetic BMS term additional secondary endpoint . C : To investigate safety - possible harm - DAPT prasugrel aspirin patient stable coronary artery disease ( CAD ) versus acute coronary syndrome ( ACS ) regard bleed event . D : To assess effect DAPT aspirin plus prasugrel versus aspirin plus clopidogrel use historical comparator cohort BASKET-PROVE ( BP ) . Secondary Endpoints 1 . Components primary endpoint . - Cardiac death - Myocardial infarction ( MI ) - Any MI - Non-fatal MI - Target vessel revascularization ( TVR ) - Any TVR - Non-MI related TVR 2 . Composite safety endpoint cardiac death non-fatal MI . 3 . Stent thrombosis accord ARC definition . - Definite - Definite probable - Definite , probable possible 4 . Major bleed include fatal bleeding , i.e. , BARC &gt; =3 . 5 . All cause death . 6 . Net clinical benefit = Primary endpoint plus major bleeding . Statistical Hypothesis , Model Method Analysis [ A1 ] Nobori DES versus ProKinetic BMS : MACE within 24 month The statistical null hypothesis difference Nobori DES ProKinetic BMS term MACE . The Cox PH model describe primary end-point include factor `` stent type '' compare Nobori DES ProKinetic BMS . In case non-proportional hazard logistic regression model use analyze incidence MACE within 24 month . [ A2 ] Nobori DES versus ProKinetic BMS , Nobori DES versus Xience Prime DES : Late harm The statistical null hypothesis difference Nobori DES Prokinetic BMS , difference Nobori DES versus Xience Prime DES term late harm . We use Cox PH model , landmark analysis time-strati ed Cox PH model ( time-intervals 0-12 month 12-24 month ) , describe primary objective , endpoint cardiac death , non-fatal MI stent thrombosis . Assessment proportional hazard assumption perform accordance method describe primary endpoint . In case non-proportional hazard , logistic regression model use analyze incidence event . [ B ] Nobori DES versus ProKinetic BMS , Nobori DES versus Xience Prime DES : Other secondary endpoint The statistical null hypothesis difference Nobori DES ProKinetic BMS , Nobori DES Xience Prime DES term secondary endpoint . All secondary endpoint 1-6 analyse use Cox PH model include factor `` stent type '' stratus ed accord `` centre '' event within 24 month - specify primary endpoint . Assessment proportional hazard assumption perform accordance method describe primary endpoint . In case non-proportional hazard , logistic regression model use analyze incidence event . Landmark analyse 0-12 12-4 month perform . Absolute probabilities event interest calculate graphically visualize use Kaplan-Meier estimator . Subgroup analyse specify primary endpoint perform secondary endpoint . [ C ] Safety DAPT prasugrel aspirin patient stable CAD regard bleed event For analysis generate four subgroup base stent type ( DES vs. BMS ) indication : 1 ) DES+Stable CAD , 2 ) DES+ACS , 3 ) BMS+Stable CAD , 4 ) BMS+ACS . The endpoint major bleeding ( BARC &gt; =3 ) , MACE ( include component ) , stent thrombosis ( see definition Section 5.1 ) analyse use Kaplan-Meier curve Cox PH model include group 4-level factor `` indication-by-stent type '' stratify factor `` centre '' . Thereby , make follow comparison : ) DES-ACS vs. DES-stable CAD , b ) BMS-ACS vs. BMS-stable CAD , c ) DES-stable CAD vs. BMS-stable CAD . In case non-proportional hazard , survival analysis complement time-independent logistic regression analysis major bleed event 24 month well cut-o point 12 month . [ D ] Comparison BP II BP regard DAPT prasugrel plus aspirin versus clopidogrel plus aspirin Two separate comparison trial make term major bleed event ( BARC &gt; =3 ) , MACE ( include component ) , stent thrombosis ( see definition Section 5.1 ) , use FAS trial ( BP : present Kaiser et al . ( 2010 ) ) : Comparison 1 DAPT ( 12 month duration ) prasugrel aspirin DES patient ( BP II ) versus DAPT ( 12 month duration ) clopidogrel aspirin DES patient ( BP ) . The statistical null-hypothesis difference rate major bleed event DAPT treatment prasugrel plus aspirin ( BP II ) versus clopidogrel plus aspirin ( BP ) patient treat DES . The endpoint major bleeding ( BARC &gt; =3 ) compare DES patient BP II DES patient BP use Cox PH model . Because patient population come two different trial rather one single randomise trial , propensity score weight analysis use balance data confound effect . The predictor calculation propensity score include potential confounders , i.e. , variable may affect treatment ( DAPT determine trial ) well outcome ( occurrence bleed event ) : age , sex , body weight , renal function , hypertension , diabetes , prior MI , etc . We use inverse probability weighting ( Hernan &amp; Robins , 2006 ) estimate e ect `` DAPT '' hazard bleeding . The Cox PH model include `` DAPT '' ( prasugrel vs. clopidogrel ) `` indication '' ( stable CAD vs. ACS ) predictor . In addition , model include interaction `` DAPT '' `` indication '' , test whether difference due type DAPT depend indication . Hazard ratios along correspond 95 % CI present . If two DES BP II ( Nobori Xience Prime ) differ regard bleeding event , MACE stent thrombosis , also include `` stent type '' predictor ( Cypher Xience BP similar ) . Comparison 2 DAPT prasugrel aspirin ( 1 month duration ) ( BP II ) versus DAPT clopidogrel aspirin ( 12 month duration ) ( BP ) stable CAD patient BMS . The statistical null-hypothesis difference rate major bleed event DAPT treatment prasugrel plus aspirin ( BP II ) versus clopidogrel plus aspirin ( BP ) stable CAD patient treat BMS . The endpoint major bleeding ( BARC &gt; =3 ) compare stable CAD patient BMS BP II stable CAD patient BMS BP use Cox PH model . As comparison 1 propensity score weight analysis perform , inverse probability weight used estimate effect `` DAPT '' hazard bleeding . Hazard ratios along correspond 95 % CI present . General In case non-proportional hazard , survival analysis complement time-independent logistic regression analysis bleed event 12 24 month , estimate odds ratio instead hazard ratio . 5.3 Handling Data Missing Values Data analyse potential extreme outlier . If present , outlier investigate . However , outlier include analysis , except clinical cause exclude . In case miss value secondary endpoint , available value use imputation miss value perform . References Hernan , M. A . &amp; Robins , J. M. 2006 : Estimating causal e ects epidemiological data . J Epidemiol Community Health 60:578-586 . Kaiser , C. ; Galatius , S. ; Erne , P. ; Eberli , F. ; Alber , H. ; Rickli , H. ; Pedrazzini , G. ; Hornig , B. ; Bertel , O. ; Bonetti , P. ; De Servi , S. ; Brunner-La Rocca , H.-P. ; Ricard , I . &amp; Pfisterer , M. 2010 : Drug-eluting versus bare-metal stent large coronary artery . New England Journal Medicine 363:2310-2319 . Newcombe , R. G. 1998 : Interval estimation difference independent pro-portions : Comparison eleven method . Statistics Medicine 17:873-890 . Windecker , S. ; Serruys , P. W. ; Wandel , S. ; Buszman , P. ; Trznadel , S. ; Linke , A. ; Lenk , K. ; Ischinger , T. ; Klauss , V. ; Eberli , F. et al . 2008 : Biolimus-eluting stent biodegrad-able polymer versus sirolimus-eluting stent durable polymer coronary revascularisation ( leader ) : randomise non-inferiority trial . The Lancet 372 ( 9644 ) :1163-1173 . Clinical Relevance : The result BPII provide evidence performance newest-generation stent market daily practice insight efficacy safety current stent design all-comer population . Moreover , BPII ass performance DAPT aspirin prasugrel compare aspirin plus clopidogrel term ischemic bleeding endpoint . - Thus , finding major impact current use coronary stent , medical antiplatelet therapy regimes understand possible reason late stent thrombosis .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Coronary Thrombosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>write informed concent need large ( ≥3.0 mm stent ) native vessel stenting inStent Restenosis inStent Thrombosis bypass graft disease stented main stem disease stented cardiogenic shock clinical assessment ( sign organ hypoperfusion ) plan surgery within next 12 month oral anticoagulation need ( artificial heart valve , atrial fibrillation ) chronic haemorrhagic diathesis active bleeding disorder indexPCI = plan PCI additional lesion followup ( FU ) expected/possible History stroke TIA ( contraindication prasugrel ) know severe hypersensitivity reaction ASS and/or Prasugrel compliance expect / inform consent give enrol another study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>coronary artery disease</keyword>
	<keyword>drug-eluting stent</keyword>
	<keyword>anti-thrombotic therapy</keyword>
	<keyword>bare-metal stent</keyword>
	<keyword>long-term outcome</keyword>
</DOC>